Scarica l'app Stockscreener
549.62
3.81%
20.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal gives seven new employees stock awards to join the company - Stock Titan
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Price to earnings forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell 1000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS: MDGL) added to Russell 1000 Index - marketscreener.com
Price to sales forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MDGL) - TradingView
MDGL Forecast — Price Target — Prediction for 2027 - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900 By Investing.com - Investing.com Canada
MDGL PE Ratio & Valuation, Is MDGL Overvalued - Intellectia AI
Madrigal Pharmaceuticals stock holds at $511.61 as SOLAR Conference event nears, Madrigal Pharmaceuticals - Traders Union
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A Biotech Gem with a 34% Upside Potential - DirectorsTalk Interviews
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Madrigal Shareholders Approve 2026 Equity Compensation Plans - The Globe and Mail
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LPmoomoo - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
Madrigal Pharmaceuticals Price Target Cut to $542.00/Share From $550.00 by B of A Securities - Moomoo
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
MDGL Q1 2026 Earnings: Narrower Loss Surprises MarketsEarnings Yield Spread - lwvtexas.org
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
1.95%
2.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):